REYKJAVIK, Iceland, July 12, 2010 /PRNewswire-FirstCall/ -- Points to Novel Pathway for Drug Discovery, Will be IncorporatedInto Tests to Improve Screening and Early Detection of Abdominal Aortic Aneurysm, Heart Attack and PAD
Scientists at deCODE genetics and academic colleagues from the Netherlands and twelve other countries
"This is the sort of discovery that makes human genetics such an exciting field of endeavour. By incorporating this with other major genetic risk factors we include in our tests, such as those on 9p21, we are empowering physicians to identify greater numbers of those at high risk and who should therefore benefit from closer monitoring and prevention strategies. In the case of AAA, for example, this can be used along with traditional risk factors to identify those who should have ultrasound screening, leading to the detection of more aneurysms earlier, potentially saving lives," said Kari Stefansson, deCODE's executive chairman and president of research.
The first phase of the study analyzed several hundred thousand SNPs across the genomes of more than 30,000 Icelandic and Dutch participants, comparing the genotypes of those diagnosed with AAA to those of control subjects. A version of the rs7025486 SNP was found to confer a 20% increase in risk of AAA, an enlargment of the aorta that, if undiagnosed or left untreated, can lead to rupture, an event that is often fatal. The SNP was then analyzed in tens of thousands of patients and controls from a dozen countries to validate the finding in AAA and to check for association with other vascular diseases. In addition to replicating the association with risk of AAA, it was also found to confer risk of heart attack and early-onset heart attack, PAD and pulmonary embolism. The latter is noteworthy because it is a disease of the veins, and has traditionally been considered distinct from arterial disease. The paper, 'Genome-wide association study identifies sequence variants within the DAB2IP gene conferring susceptibility to abdominal aortic aneurysm,' is published online in Nature Genetics at http://www.nature.com/ng and will appear in an upcoming print edition of the journal.
Headquartered in Reykjavik, Iceland, deCODE genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered key genetic risk factors for dozens of common diseases ranging from cardiovascular disease to cancer. deCODE employs its capabilities to develop DNA-based tests and personal genome scans to better understand individual risk and empower prevention. It also licenses its tests, intellectual property and analytical tools to partners, and provides comprehensive genotyping, sequencing and data analysis services to companies and research institutions around the globe. Through its CLIA- and CAP-certified laboratory deCODE offers DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2(TM) for type 2 diabetes; deCODE AF(TM) for atrial fibrillation and stroke; deCODE MI(TM) for heart attack; deCODE ProstateCancer(TM) for prostate cancer; deCODE Glaucoma(TM) for a major type of glaucoma; and deCODE BreastCancer, for the common forms of breast cancer. Through its pioneering personal genome analysis service deCODEme(TM), deCODE enables individuals to better understand their risk of dozens of common diseases and to learn about their ancestry and other traits. Visit us on the web at http://www.decode.com; at http://www.decodediagnostics.com; at http://www.decodeme.com; and on our blog at http://www.decodeyou.com.
Contacts: Edward Farmer Gisli Arnason +44-7796-010107 +354-570-1825 [email protected] [email protected]
SOURCE DeCODE Genetics Inc
Subscribe to our Free Newsletters!
Hyperacusis is a chronic hearing disorder characterized by an abnormal sensitivity to s ...
Proton beam therapy is a type of external radiation treatment or radiotherapy that uses protons ...
Statins are a group of drugs which help to lower the blood cholesterol levels.View All